<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00291642</url>
  </required_header>
  <id_info>
    <org_study_id>A00412</org_study_id>
    <nct_id>NCT00291642</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Efficacy of Levocetirizine to Placebo in Reducing Symptoms of Seasonal Allergic Rhinitis (SAR) in Sensitive Subjects Exposed to Ragweed Pollen</brief_title>
  <official_title>Double Blind, Double-dummy, Five Parallel Groups, Randomized, Exploratory Clinical Trial to Compare the Efficacy of Single Dose of Levocetirizine 2.5 mg Oral Drops (5 mg/mL), Levocetirizine 5 mg Oral Tablets, Cetirizine 5 mg Oral Drops (10 mg/mL) and Cetirizine 10 mg Oral Tablets to Placebo in Reducing Symptoms of Seasonal Allergic Rhinitis (SAR) in Ragweed Sensitive Subjects Exposed to Ragweed Pollen in an Environmental Exposure Unit (EEU)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the efficacy comparability of cetirizine and
      levocetirizine, by comparing the effects of single intake of the two drugs to placebo in
      reducing symptoms of seasonal allergic rhinitis (SAR) in ragweed sensitive adult subjects
      exposed to ragweed pollen in an Environmental Exposure Unit.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 1, 2006</start_date>
  <completion_date type="Actual">April 1, 2006</completion_date>
  <primary_completion_date type="Actual">April 1, 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in the Major Symptom Complex (MSC) Score Over Period I</measure>
    <time_frame>Baseline, Treatment Period 1 [Day 1, from drug intake (at 11:00 am) to 5 hours post-treatment (at 4:00 pm)]</time_frame>
    <description>Six individual symptoms which are most dominant in the rhinitis symptom profile will be combined to form the MSC severity score:
Runny nose (right and left), itchy nose (right and left), sniffles, nose blows, sneezes, watery eyes.
Each individual symptom, except nose blows and sneezes, is rated on a 5-point scale of severity: 0 = None, 1 = a little, 2 = Moderate, 3 = Quite a bit, 4 = severe, 5 = very severe. For nose blows and sneezes, the subjects had to record the number of each symptom since last evaluation. This number corresponds to a score ranging from 0 to 8. The total MSC score ranges from 0 - 36. Increasing scores are associated with increasing severity. Negative values indicate improvement from Baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the MSC Score Over Period II</measure>
    <time_frame>Baseline, Treatment Period II [Day 2, (8:30 am to 12:00 pm)]</time_frame>
    <description>Six individual symptoms which are most dominant in the rhinitis symptom profile will be combined to form the MSC severity score:
Runny nose (right and left), itchy nose (right and left), sniffles, nose blows, sneezes, watery eyes.
Each individual symptom, except nose blows and sneezes, is rated on a 5-point scale of severity: 0 = None, 1 = a little, 2 = Moderate, 3 = Quite a bit, 4 = severe, 5 = very severe. For nose blows and sneezes, the subjects had to record the number of each symptom since last evaluation. This number corresponds to a score ranging from 0 to 8. The total MSC score ranges from 0 - 36. Increasing scores are associated with increasing severity. Negative values indicate improvement from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the MSC Score Over the Total Treatment Period (Period I + Period II)</measure>
    <time_frame>Baseline to Day 2</time_frame>
    <description>Six individual symptoms which are most dominant in the rhinitis symptom profile will be combined to form the MSC severity score:
Runny nose (right and left), itchy nose (right and left), sniffles, nose blows, sneezes, watery eyes.
Each individual symptom, except nose blows and sneezes, is rated on a 5-point scale of severity: 0 = None, 1 = a little, 2 = Moderate, 3 = Quite a bit, 4 = severe, 5 = very severe. For nose blows and sneezes, the subjects had to record the number of each symptom since last evaluation. This number corresponds to a score ranging from 0 to 8. The total MSC score ranges from 0 - 36. Increasing scores are associated with increasing severity. Negative values indicate improvement from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Total Symptom Complex (TSC) Score Over Period I</measure>
    <time_frame>Baseline, Treatment Period I [Day 1, from drug intake (at 11:00 am) to 5 hours post-treatment (at 4:00 pm)]</time_frame>
    <description>The TSC score was calculated as the sum of the following 10 individual symptom scores:
runny nose (left and right), itchy nose (left and right), sniffles, nose blows, sneezes, watery eyes, itchy eyes and ears, itchy throat, cough and postnasal drip.
Each individual symptom, except nose blows and sneezes, is rated on a 5-point scale of severity: 0 = None, 1 = a little, 2 = Moderate, 3 = Quite a bit, 4 = severe, 5 = very severe. For nose blows and sneezes, the subjects had to record the number of each symptom since last evaluation. This number corresponds to a score ranging from 0 to 8. The TSC score ranges from 0 to 56. Increasing scores are associated with increasing severity. Negative values indicate improvement from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Total Symptom Complex (TSC) Score Over Period II</measure>
    <time_frame>Baseline, Treatment Period II [Day 2, (8:30 am to 12:00 pm)]</time_frame>
    <description>The TSC score was calculated as the sum of the following 10 individual symptom scores:
runny nose (left and right), itchy nose (left and right), sniffles, nose blows, sneezes, watery eyes, itchy eyes and ears, itchy throat, cough and postnasal drip.
Each individual symptom, except nose blows and sneezes, is rated on a 5-point scale of severity: 0 = None, 1 = a little, 2 = Moderate, 3 = Quite a bit, 4 = severe, 5 = very severe. For nose blows and sneezes, the subjects had to record the number of each symptom since last evaluation. This number corresponds to a score ranging from 0 to 8. The TSC score ranges from 0 to 56. Increasing scores are associated with increasing severity. Negative values indicate improvement from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Total Symptom Complex (TSC) Score Over the Total Treatment Period (Period I + Period II)</measure>
    <time_frame>Baseline to Day 2</time_frame>
    <description>The TSC score was calculated as the sum of the following 10 individual symptom scores:
runny nose (left and right), itchy nose (left and right), sniffles, nose blows, sneezes, watery eyes, itchy eyes and ears, itchy throat, cough and postnasal drip.
Each individual symptom, except nose blows and sneezes, is rated on a 5-point scale of severity: 0 = None, 1 = a little, 2 = Moderate, 3 = Quite a bit, 4 = severe, 5 = very severe. For nose blows and sneezes, the subjects had to record the number of each symptom since last evaluation. This number corresponds to a score ranging from 0 to 8. The TSC score ranges from 0 to 56. Increasing scores are associated with increasing severity. Negative values indicate improvement from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Individual Symptom Scores Over Period I</measure>
    <time_frame>Baseline, Treatment Period 1 [Day 1, from drug intake (at 11:00 am) to 5 hours post-treatment (at 4:00 pm)]</time_frame>
    <description>Individual symptom scores include Runny Nose Score, Itchy Nose Score, Sniffles Score, Watery Eyes Score, Sneezes Score, Nose Blows Score.
The subjects had to evaluate the severity of the symptoms using a scale from &quot;None&quot; to &quot;Very severe&quot; (ranging from 0 to 5).
For Sneezes Score and Nose Blows Score, the subjects had to record the number of each symptom since last evaluation. This number corresponds to a score ranging from 0 to 8.
Increasing scores are associated with increasing severity. Negative values indicate improvement from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Individual Symptom Scores Over Period II</measure>
    <time_frame>Baseline, Treatment Period II [Day 2, (8:30 am to 12:00 pm)]</time_frame>
    <description>Individual symptom scores include Runny Nose Score, Itchy Nose Score, Sniffles Score, Watery Eyes Score, Sneezes Score, Nose Blows Score.
The subjects had to evaluate the severity of the symptoms using a scale from &quot;None&quot; to &quot;Very severe&quot; (ranging from 0 to 5).
For Sneezes Score and Nose Blows Score, the subjects had to record the number of each symptom since last evaluation. This number corresponds to a score ranging from 0 to 8.
Increasing scores are associated with increasing severity. Negative values indicate improvement from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Individual Symptom Scores Over the Total Treatment Period (Period I + Period II)</measure>
    <time_frame>Baseline to Day 2</time_frame>
    <description>Individual symptom scores include Runny Nose Score, Itchy Nose Score, Sniffles Score, Watery Eyes Score, Sneezes Score, Nose Blows Score.
The subjects had to evaluate the severity of the symptoms using a scale from &quot;None&quot; to &quot;Very severe&quot; (ranging from 0 to 5).
For Sneezes Score and Nose Blows Score, the subjects had to record the number of each symptom since last evaluation. This number corresponds to a score ranging from 0 to 8.
Increasing scores are associated with increasing severity. Negative values indicate improvement from Baseline.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">551</enrollment>
  <condition>Rhinitis</condition>
  <condition>Allergic</condition>
  <condition>Seasonal</condition>
  <arm_group>
    <arm_group_label>Placebo (PBO)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single dose of placebo was administered orally on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levocetirizine (LCTZ) 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of 2.5 mg of LCTZ oral drops was administered orally on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levocetirizine (LCTZ) 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of 5 mg of LCTZ oral tablet was administered orally on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cetirizine (CTZ) 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of 5 mg of CTZ oral drops was administered orally on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cetirizine (CTZ) 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of 10 mg of CTZ oral tablet was administered orally on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo drops</intervention_name>
    <description>Pharmaceutical form: Drops for oral administration
Route of administration: Oral use</description>
    <arm_group_label>Placebo (PBO)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablets matching to levocetirizine</intervention_name>
    <description>Pharmaceutical form: Tablets for oral administration
Route of administration: Oral use</description>
    <arm_group_label>Placebo (PBO)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablets matching to cetirizine</intervention_name>
    <description>Pharmaceutical form: Tablets for oral administration
Route of administration: Oral use</description>
    <arm_group_label>Placebo (PBO)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levocetirizine drops</intervention_name>
    <description>Pharmaceutical form: Drops for oral administration
Concentration: 5 mg/ml
Route of administration: Oral use</description>
    <arm_group_label>Levocetirizine (LCTZ) 2.5 mg</arm_group_label>
    <other_name>Xyzal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levocetirizine tablets</intervention_name>
    <description>Pharmaceutical form: Tablets for oral administration
Concentration: 5 mg
Route of administration: Oral use</description>
    <arm_group_label>Levocetirizine (LCTZ) 5 mg</arm_group_label>
    <other_name>Xyzal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetirizine drops</intervention_name>
    <description>Pharmaceutical form: Drops for oral administration
Concentration: 10 mg/ml
Route of administration: Oral use</description>
    <arm_group_label>Cetirizine (CTZ) 5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetirizine tablets</intervention_name>
    <description>Pharmaceutical form: Tablets for oral administration
Concentration: 10 mg
Route of administration: Oral use</description>
    <arm_group_label>Cetirizine (CTZ) 10 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female subject of non-childbearing potential or of childbearing potential agreeing not
             to become pregnant during the study.

          -  Have had seasonal allergic rhinitis due to Ragweed for the last 2 consecutive years

          -  Subjects who obtain a minimum sum considering SAR related symptoms (mean value) as
             defined by protocol

        Exclusion Criteria:

          -  Any clinically significant condition that might interfere with the treatment
             evaluation, both for efficacy and safety

          -  Have used forbidden concomitant medications as defined by the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Study Director</role>
    <affiliation>UCB (+1 844 599 2273)</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.ucb.com/_up/ucb_com_patients/documents/A00412_CSS_20070720.pdf</url>
    <description>Clinical Study Summary on UCB.com</description>
  </link>
  <link>
    <url>http://products.sanofi-aventis.us/xyzal/xyzal.pdf</url>
    <description>Product Information</description>
  </link>
  <link>
    <url>http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>August 1, 2018</verification_date>
  <study_first_submitted>February 10, 2006</study_first_submitted>
  <study_first_submitted_qc>February 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2006</study_first_posted>
  <results_first_submitted>October 10, 2017</results_first_submitted>
  <results_first_submitted_qc>October 10, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 20, 2018</results_first_posted>
  <last_update_submitted>August 13, 2018</last_update_submitted>
  <last_update_submitted_qc>August 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Levocetirizine</keyword>
  <keyword>Xyzal</keyword>
  <keyword>Rhinitis</keyword>
  <keyword>Allergic</keyword>
  <keyword>Seasonal</keyword>
  <keyword>Ragweed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetirizine</mesh_term>
    <mesh_term>Levocetirizine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participant Flow refers to the Randomized Set.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo (PBO)</title>
          <description>A single dose of placebo was administered orally on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Levocetirizine (LCTZ) 2.5 mg</title>
          <description>A single dose of 2.5 mg of LCTZ oral drops was administered orally on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>Levocetirizine (LCTZ) 5 mg</title>
          <description>A single dose of 5 mg of LCTZ oral tablet was administered orally on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>Cetirizine (CTZ) 5 mg</title>
          <description>A single dose of 5 mg of CTZ oral drops was administered orally on Day 1.</description>
        </group>
        <group group_id="P5">
          <title>Cetirizine (CTZ) 10 mg</title>
          <description>A single dose of 10 mg of CTZ oral tablet was administered orally on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="116"/>
                <participants group_id="P3" count="119"/>
                <participants group_id="P4" count="119"/>
                <participants group_id="P5" count="119"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="116"/>
                <participants group_id="P3" count="117"/>
                <participants group_id="P4" count="119"/>
                <participants group_id="P5" count="118"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient missed visit</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Intake of prohibited medication</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Characteristics refer to the Intention-to-Treat (ITT) Set.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo (PBO)</title>
          <description>A single dose of placebo was administered orally on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Levocetirizine (LCTZ) 2.5 mg</title>
          <description>A single dose of 2.5 mg of LCTZ oral drops was administered orally on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Levocetirizine (LCTZ) 5 mg</title>
          <description>A single dose of 5 mg of LCTZ oral tablet was administered orally on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>Cetirizine (CTZ) 5 mg</title>
          <description>A single dose of 5 mg of CTZ oral drops was administered orally on Day 1.</description>
        </group>
        <group group_id="B5">
          <title>Cetirizine (CTZ) 10 mg</title>
          <description>A single dose of 10 mg of CTZ oral tablet was administered orally on Day 1.</description>
        </group>
        <group group_id="B6">
          <title>Total Title</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="78"/>
            <count group_id="B2" value="116"/>
            <count group_id="B3" value="119"/>
            <count group_id="B4" value="119"/>
            <count group_id="B5" value="119"/>
            <count group_id="B6" value="551"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="114"/>
                    <measurement group_id="B4" value="113"/>
                    <measurement group_id="B5" value="114"/>
                    <measurement group_id="B6" value="530"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.71" spread="12.46"/>
                    <measurement group_id="B2" value="33.45" spread="11.28"/>
                    <measurement group_id="B3" value="34.36" spread="12.84"/>
                    <measurement group_id="B4" value="32.91" spread="11.30"/>
                    <measurement group_id="B5" value="34.33" spread="11.65"/>
                    <measurement group_id="B6" value="33.76" spread="11.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="65"/>
                    <measurement group_id="B5" value="72"/>
                    <measurement group_id="B6" value="312"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="54"/>
                    <measurement group_id="B5" value="47"/>
                    <measurement group_id="B6" value="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Major Symptom Complex (MSC) Score Over Period I</title>
        <description>Six individual symptoms which are most dominant in the rhinitis symptom profile will be combined to form the MSC severity score:
Runny nose (right and left), itchy nose (right and left), sniffles, nose blows, sneezes, watery eyes.
Each individual symptom, except nose blows and sneezes, is rated on a 5-point scale of severity: 0 = None, 1 = a little, 2 = Moderate, 3 = Quite a bit, 4 = severe, 5 = very severe. For nose blows and sneezes, the subjects had to record the number of each symptom since last evaluation. This number corresponds to a score ranging from 0 to 8. The total MSC score ranges from 0 - 36. Increasing scores are associated with increasing severity. Negative values indicate improvement from Baseline.</description>
        <time_frame>Baseline, Treatment Period 1 [Day 1, from drug intake (at 11:00 am) to 5 hours post-treatment (at 4:00 pm)]</time_frame>
        <population>Only patients with valid MSC scores in Period I were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO)</title>
            <description>A single dose of placebo was administered orally on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Levocetirizine (LCTZ) 2.5 mg</title>
            <description>A single dose of 2.5 mg of LCTZ oral drops was administered orally on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Levocetirizine (LCTZ) 5 mg</title>
            <description>A single dose of 5 mg of LCTZ oral tablet was administered orally on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cetirizine (CTZ) 5 mg</title>
            <description>A single dose of 5 mg of CTZ oral drops was administered orally on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cetirizine (CTZ) 10 mg</title>
            <description>A single dose of 10 mg of CTZ oral tablet was administered orally on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Major Symptom Complex (MSC) Score Over Period I</title>
          <description>Six individual symptoms which are most dominant in the rhinitis symptom profile will be combined to form the MSC severity score:
Runny nose (right and left), itchy nose (right and left), sniffles, nose blows, sneezes, watery eyes.
Each individual symptom, except nose blows and sneezes, is rated on a 5-point scale of severity: 0 = None, 1 = a little, 2 = Moderate, 3 = Quite a bit, 4 = severe, 5 = very severe. For nose blows and sneezes, the subjects had to record the number of each symptom since last evaluation. This number corresponds to a score ranging from 0 to 8. The total MSC score ranges from 0 - 36. Increasing scores are associated with increasing severity. Negative values indicate improvement from Baseline.</description>
          <population>Only patients with valid MSC scores in Period I were included in the analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="119"/>
                <count group_id="O4" value="119"/>
                <count group_id="O5" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.80" spread="0.495"/>
                    <measurement group_id="O2" value="-7.15" spread="0.406"/>
                    <measurement group_id="O3" value="-7.05" spread="0.401"/>
                    <measurement group_id="O4" value="-7.93" spread="0.401"/>
                    <measurement group_id="O5" value="-7.54" spread="0.401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.640</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.61</ci_lower_limit>
            <ci_upper_limit>-2.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.637</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.50</ci_lower_limit>
            <ci_upper_limit>-2.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.637</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.38</ci_lower_limit>
            <ci_upper_limit>-2.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.74</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.637</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.99</ci_lower_limit>
            <ci_upper_limit>-2.49</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the MSC Score Over Period II</title>
        <description>Six individual symptoms which are most dominant in the rhinitis symptom profile will be combined to form the MSC severity score:
Runny nose (right and left), itchy nose (right and left), sniffles, nose blows, sneezes, watery eyes.
Each individual symptom, except nose blows and sneezes, is rated on a 5-point scale of severity: 0 = None, 1 = a little, 2 = Moderate, 3 = Quite a bit, 4 = severe, 5 = very severe. For nose blows and sneezes, the subjects had to record the number of each symptom since last evaluation. This number corresponds to a score ranging from 0 to 8. The total MSC score ranges from 0 - 36. Increasing scores are associated with increasing severity. Negative values indicate improvement from Baseline.</description>
        <time_frame>Baseline, Treatment Period II [Day 2, (8:30 am to 12:00 pm)]</time_frame>
        <population>Only patients with valid MSC scores in Period II were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO)</title>
            <description>A single dose of placebo was administered orally on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Levocetirizine (LCTZ) 2.5 mg</title>
            <description>A single dose of 2.5 mg of LCTZ oral drops was administered orally on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Levocetirizine (LCTZ) 5 mg</title>
            <description>A single dose of 5 mg of LCTZ oral tablet was administered orally on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cetirizine (CTZ) 5 mg</title>
            <description>A single dose of 5 mg of CTZ oral drops was administered orally on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cetirizine (CTZ) 10 mg</title>
            <description>A single dose of 10 mg of CTZ oral tablet was administered orally on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the MSC Score Over Period II</title>
          <description>Six individual symptoms which are most dominant in the rhinitis symptom profile will be combined to form the MSC severity score:
Runny nose (right and left), itchy nose (right and left), sniffles, nose blows, sneezes, watery eyes.
Each individual symptom, except nose blows and sneezes, is rated on a 5-point scale of severity: 0 = None, 1 = a little, 2 = Moderate, 3 = Quite a bit, 4 = severe, 5 = very severe. For nose blows and sneezes, the subjects had to record the number of each symptom since last evaluation. This number corresponds to a score ranging from 0 to 8. The total MSC score ranges from 0 - 36. Increasing scores are associated with increasing severity. Negative values indicate improvement from Baseline.</description>
          <population>Only patients with valid MSC scores in Period II were included in the analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="119"/>
                <count group_id="O5" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.50" spread="0.604"/>
                    <measurement group_id="O2" value="-6.35" spread="0.489"/>
                    <measurement group_id="O3" value="-7.07" spread="0.487"/>
                    <measurement group_id="O4" value="-6.78" spread="0.483"/>
                    <measurement group_id="O5" value="-7.92" spread="0.485"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the MSC Score Over the Total Treatment Period (Period I + Period II)</title>
        <description>Six individual symptoms which are most dominant in the rhinitis symptom profile will be combined to form the MSC severity score:
Runny nose (right and left), itchy nose (right and left), sniffles, nose blows, sneezes, watery eyes.
Each individual symptom, except nose blows and sneezes, is rated on a 5-point scale of severity: 0 = None, 1 = a little, 2 = Moderate, 3 = Quite a bit, 4 = severe, 5 = very severe. For nose blows and sneezes, the subjects had to record the number of each symptom since last evaluation. This number corresponds to a score ranging from 0 to 8. The total MSC score ranges from 0 - 36. Increasing scores are associated with increasing severity. Negative values indicate improvement from Baseline.</description>
        <time_frame>Baseline to Day 2</time_frame>
        <population>Only patients with valid MSC scores in Period I and II were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO)</title>
            <description>A single dose of placebo was administered orally on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Levocetirizine (LCTZ) 2.5 mg</title>
            <description>A single dose of 2.5 mg of LCTZ oral drops was administered orally on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Levocetirizine (LCTZ) 5 mg</title>
            <description>A single dose of 5 mg of LCTZ oral tablet was administered orally on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cetirizine (CTZ) 5 mg</title>
            <description>A single dose of 5 mg of CTZ oral drops was administered orally on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cetirizine (CTZ) 10 mg</title>
            <description>A single dose of 10 mg of CTZ oral tablet was administered orally on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the MSC Score Over the Total Treatment Period (Period I + Period II)</title>
          <description>Six individual symptoms which are most dominant in the rhinitis symptom profile will be combined to form the MSC severity score:
Runny nose (right and left), itchy nose (right and left), sniffles, nose blows, sneezes, watery eyes.
Each individual symptom, except nose blows and sneezes, is rated on a 5-point scale of severity: 0 = None, 1 = a little, 2 = Moderate, 3 = Quite a bit, 4 = severe, 5 = very severe. For nose blows and sneezes, the subjects had to record the number of each symptom since last evaluation. This number corresponds to a score ranging from 0 to 8. The total MSC score ranges from 0 - 36. Increasing scores are associated with increasing severity. Negative values indicate improvement from Baseline.</description>
          <population>Only patients with valid MSC scores in Period I and II were included in the analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="119"/>
                <count group_id="O4" value="119"/>
                <count group_id="O5" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.61" spread="0.473"/>
                    <measurement group_id="O2" value="-6.80" spread="0.388"/>
                    <measurement group_id="O3" value="-7.10" spread="0.383"/>
                    <measurement group_id="O4" value="-7.43" spread="0.384"/>
                    <measurement group_id="O5" value="-7.72" spread="0.383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Total Symptom Complex (TSC) Score Over Period I</title>
        <description>The TSC score was calculated as the sum of the following 10 individual symptom scores:
runny nose (left and right), itchy nose (left and right), sniffles, nose blows, sneezes, watery eyes, itchy eyes and ears, itchy throat, cough and postnasal drip.
Each individual symptom, except nose blows and sneezes, is rated on a 5-point scale of severity: 0 = None, 1 = a little, 2 = Moderate, 3 = Quite a bit, 4 = severe, 5 = very severe. For nose blows and sneezes, the subjects had to record the number of each symptom since last evaluation. This number corresponds to a score ranging from 0 to 8. The TSC score ranges from 0 to 56. Increasing scores are associated with increasing severity. Negative values indicate improvement from Baseline.</description>
        <time_frame>Baseline, Treatment Period I [Day 1, from drug intake (at 11:00 am) to 5 hours post-treatment (at 4:00 pm)]</time_frame>
        <population>Only patients with valid TSC scores in Period I were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO)</title>
            <description>A single dose of placebo was administered orally on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Levocetirizine (LCTZ) 2.5 mg</title>
            <description>A single dose of 2.5 mg of LCTZ oral drops was administered orally on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Levocetirizine (LCTZ) 5 mg</title>
            <description>A single dose of 5 mg of LCTZ oral tablet was administered orally on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cetirizine (CTZ) 5 mg</title>
            <description>A single dose of 5 mg of CTZ oral drops was administered orally on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cetirizine (CTZ) 10 mg</title>
            <description>A single dose of 10 mg of CTZ oral tablet was administered orally on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Total Symptom Complex (TSC) Score Over Period I</title>
          <description>The TSC score was calculated as the sum of the following 10 individual symptom scores:
runny nose (left and right), itchy nose (left and right), sniffles, nose blows, sneezes, watery eyes, itchy eyes and ears, itchy throat, cough and postnasal drip.
Each individual symptom, except nose blows and sneezes, is rated on a 5-point scale of severity: 0 = None, 1 = a little, 2 = Moderate, 3 = Quite a bit, 4 = severe, 5 = very severe. For nose blows and sneezes, the subjects had to record the number of each symptom since last evaluation. This number corresponds to a score ranging from 0 to 8. The TSC score ranges from 0 to 56. Increasing scores are associated with increasing severity. Negative values indicate improvement from Baseline.</description>
          <population>Only patients with valid TSC scores in Period I were included in the analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="119"/>
                <count group_id="O4" value="119"/>
                <count group_id="O5" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.55" spread="0.757"/>
                    <measurement group_id="O2" value="-11.33" spread="0.620"/>
                    <measurement group_id="O3" value="-11.27" spread="0.613"/>
                    <measurement group_id="O4" value="-12.71" spread="0.613"/>
                    <measurement group_id="O5" value="-11.74" spread="0.613"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Total Symptom Complex (TSC) Score Over Period II</title>
        <description>The TSC score was calculated as the sum of the following 10 individual symptom scores:
runny nose (left and right), itchy nose (left and right), sniffles, nose blows, sneezes, watery eyes, itchy eyes and ears, itchy throat, cough and postnasal drip.
Each individual symptom, except nose blows and sneezes, is rated on a 5-point scale of severity: 0 = None, 1 = a little, 2 = Moderate, 3 = Quite a bit, 4 = severe, 5 = very severe. For nose blows and sneezes, the subjects had to record the number of each symptom since last evaluation. This number corresponds to a score ranging from 0 to 8. The TSC score ranges from 0 to 56. Increasing scores are associated with increasing severity. Negative values indicate improvement from Baseline.</description>
        <time_frame>Baseline, Treatment Period II [Day 2, (8:30 am to 12:00 pm)]</time_frame>
        <population>Only patients with valid TSC scores in Period II were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO)</title>
            <description>A single dose of placebo was administered orally on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Levocetirizine (LCTZ) 2.5 mg</title>
            <description>A single dose of 2.5 mg of LCTZ oral drops was administered orally on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Levocetirizine (LCTZ) 5 mg</title>
            <description>A single dose of 5 mg of LCTZ oral tablet was administered orally on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cetirizine (CTZ) 5 mg</title>
            <description>A single dose of 5 mg of CTZ oral drops was administered orally on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cetirizine (CTZ) 10 mg</title>
            <description>A single dose of 10 mg of CTZ oral tablet was administered orally on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Total Symptom Complex (TSC) Score Over Period II</title>
          <description>The TSC score was calculated as the sum of the following 10 individual symptom scores:
runny nose (left and right), itchy nose (left and right), sniffles, nose blows, sneezes, watery eyes, itchy eyes and ears, itchy throat, cough and postnasal drip.
Each individual symptom, except nose blows and sneezes, is rated on a 5-point scale of severity: 0 = None, 1 = a little, 2 = Moderate, 3 = Quite a bit, 4 = severe, 5 = very severe. For nose blows and sneezes, the subjects had to record the number of each symptom since last evaluation. This number corresponds to a score ranging from 0 to 8. The TSC score ranges from 0 to 56. Increasing scores are associated with increasing severity. Negative values indicate improvement from Baseline.</description>
          <population>Only patients with valid TSC scores in Period II were included in the analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="119"/>
                <count group_id="O5" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.73" spread="0.917"/>
                    <measurement group_id="O2" value="-10.25" spread="0.742"/>
                    <measurement group_id="O3" value="-11.03" spread="0.739"/>
                    <measurement group_id="O4" value="-10.73" spread="0.734"/>
                    <measurement group_id="O5" value="-12.14" spread="0.736"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Total Symptom Complex (TSC) Score Over the Total Treatment Period (Period I + Period II)</title>
        <description>The TSC score was calculated as the sum of the following 10 individual symptom scores:
runny nose (left and right), itchy nose (left and right), sniffles, nose blows, sneezes, watery eyes, itchy eyes and ears, itchy throat, cough and postnasal drip.
Each individual symptom, except nose blows and sneezes, is rated on a 5-point scale of severity: 0 = None, 1 = a little, 2 = Moderate, 3 = Quite a bit, 4 = severe, 5 = very severe. For nose blows and sneezes, the subjects had to record the number of each symptom since last evaluation. This number corresponds to a score ranging from 0 to 8. The TSC score ranges from 0 to 56. Increasing scores are associated with increasing severity. Negative values indicate improvement from Baseline.</description>
        <time_frame>Baseline to Day 2</time_frame>
        <population>Only patients with valid TSC scores in Period I and II were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO)</title>
            <description>A single dose of placebo was administered orally on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Levocetirizine (LCTZ) 2.5 mg</title>
            <description>A single dose of 2.5 mg of LCTZ oral drops was administered orally on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Levocetirizine (LCTZ) 5 mg</title>
            <description>A single dose of 5 mg of LCTZ oral tablet was administered orally on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cetirizine (CTZ) 5 mg</title>
            <description>A single dose of 5 mg of CTZ oral drops was administered orally on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cetirizine (CTZ) 10 mg</title>
            <description>A single dose of 10 mg of CTZ oral tablet was administered orally on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Total Symptom Complex (TSC) Score Over the Total Treatment Period (Period I + Period II)</title>
          <description>The TSC score was calculated as the sum of the following 10 individual symptom scores:
runny nose (left and right), itchy nose (left and right), sniffles, nose blows, sneezes, watery eyes, itchy eyes and ears, itchy throat, cough and postnasal drip.
Each individual symptom, except nose blows and sneezes, is rated on a 5-point scale of severity: 0 = None, 1 = a little, 2 = Moderate, 3 = Quite a bit, 4 = severe, 5 = very severe. For nose blows and sneezes, the subjects had to record the number of each symptom since last evaluation. This number corresponds to a score ranging from 0 to 8. The TSC score ranges from 0 to 56. Increasing scores are associated with increasing severity. Negative values indicate improvement from Baseline.</description>
          <population>Only patients with valid TSC scores in Period I and II were included in the analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="119"/>
                <count group_id="O4" value="119"/>
                <count group_id="O5" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.10" spread="0.729"/>
                    <measurement group_id="O2" value="-10.86" spread="0.598"/>
                    <measurement group_id="O3" value="-11.22" spread="0.591"/>
                    <measurement group_id="O4" value="-11.84" spread="0.591"/>
                    <measurement group_id="O5" value="-11.92" spread="0.591"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Individual Symptom Scores Over Period I</title>
        <description>Individual symptom scores include Runny Nose Score, Itchy Nose Score, Sniffles Score, Watery Eyes Score, Sneezes Score, Nose Blows Score.
The subjects had to evaluate the severity of the symptoms using a scale from &quot;None&quot; to &quot;Very severe&quot; (ranging from 0 to 5).
For Sneezes Score and Nose Blows Score, the subjects had to record the number of each symptom since last evaluation. This number corresponds to a score ranging from 0 to 8.
Increasing scores are associated with increasing severity. Negative values indicate improvement from Baseline.</description>
        <time_frame>Baseline, Treatment Period 1 [Day 1, from drug intake (at 11:00 am) to 5 hours post-treatment (at 4:00 pm)]</time_frame>
        <population>Only subjects with valid individual symptom scores in Period I were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO)</title>
            <description>A single dose of placebo was administered orally on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Levocetirizine (LCTZ) 2.5 mg</title>
            <description>A single dose of 2.5 mg of LCTZ oral drops was administered orally on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Levocetirizine (LCTZ) 5 mg</title>
            <description>A single dose of 5 mg of LCTZ oral tablet was administered orally on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cetirizine (CTZ) 5 mg</title>
            <description>A single dose of 5 mg of CTZ oral drops was administered orally on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cetirizine (CTZ) 10 mg</title>
            <description>A single dose of 10 mg of CTZ oral tablet was administered orally on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Individual Symptom Scores Over Period I</title>
          <description>Individual symptom scores include Runny Nose Score, Itchy Nose Score, Sniffles Score, Watery Eyes Score, Sneezes Score, Nose Blows Score.
The subjects had to evaluate the severity of the symptoms using a scale from &quot;None&quot; to &quot;Very severe&quot; (ranging from 0 to 5).
For Sneezes Score and Nose Blows Score, the subjects had to record the number of each symptom since last evaluation. This number corresponds to a score ranging from 0 to 8.
Increasing scores are associated with increasing severity. Negative values indicate improvement from Baseline.</description>
          <population>Only subjects with valid individual symptom scores in Period I were included in the analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="119"/>
                <count group_id="O4" value="119"/>
                <count group_id="O5" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Runny Nose Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" spread="0.095"/>
                    <measurement group_id="O2" value="-1.01" spread="0.078"/>
                    <measurement group_id="O3" value="-0.95" spread="0.077"/>
                    <measurement group_id="O4" value="-1.17" spread="0.077"/>
                    <measurement group_id="O5" value="-1.04" spread="0.077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itchy Nose Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.66" spread="0.099"/>
                    <measurement group_id="O2" value="-1.03" spread="0.082"/>
                    <measurement group_id="O3" value="-1.09" spread="0.081"/>
                    <measurement group_id="O4" value="-1.28" spread="0.081"/>
                    <measurement group_id="O5" value="-1.10" spread="0.081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sniffles Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65" spread="0.100"/>
                    <measurement group_id="O2" value="-1.15" spread="0.082"/>
                    <measurement group_id="O3" value="-1.06" spread="0.081"/>
                    <measurement group_id="O4" value="-1.24" spread="0.081"/>
                    <measurement group_id="O5" value="-1.10" spread="0.081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nose Blow Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.98" spread="0.129"/>
                    <measurement group_id="O2" value="-1.87" spread="0.106"/>
                    <measurement group_id="O3" value="-1.82" spread="0.105"/>
                    <measurement group_id="O4" value="-1.92" spread="0.105"/>
                    <measurement group_id="O5" value="-1.96" spread="0.105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sneezes Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.103"/>
                    <measurement group_id="O2" value="-1.15" spread="0.084"/>
                    <measurement group_id="O3" value="-1.07" spread="0.083"/>
                    <measurement group_id="O4" value="-1.22" spread="0.083"/>
                    <measurement group_id="O5" value="-1.23" spread="0.083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Watery Eyes Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.56" spread="0.090"/>
                    <measurement group_id="O2" value="-0.94" spread="0.074"/>
                    <measurement group_id="O3" value="-1.08" spread="0.073"/>
                    <measurement group_id="O4" value="-1.13" spread="0.073"/>
                    <measurement group_id="O5" value="-1.07" spread="0.073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Individual Symptom Scores Over Period II</title>
        <description>Individual symptom scores include Runny Nose Score, Itchy Nose Score, Sniffles Score, Watery Eyes Score, Sneezes Score, Nose Blows Score.
The subjects had to evaluate the severity of the symptoms using a scale from &quot;None&quot; to &quot;Very severe&quot; (ranging from 0 to 5).
For Sneezes Score and Nose Blows Score, the subjects had to record the number of each symptom since last evaluation. This number corresponds to a score ranging from 0 to 8.
Increasing scores are associated with increasing severity. Negative values indicate improvement from Baseline.</description>
        <time_frame>Baseline, Treatment Period II [Day 2, (8:30 am to 12:00 pm)]</time_frame>
        <population>Only subjects with valid individual symptom scores in Period II were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO)</title>
            <description>A single dose of placebo was administered orally on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Levocetirizine (LCTZ) 2.5 mg</title>
            <description>A single dose of 2.5 mg of LCTZ oral drops was administered orally on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Levocetirizine (LCTZ) 5 mg</title>
            <description>A single dose of 5 mg of LCTZ oral tablet was administered orally on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cetirizine (CTZ) 5 mg</title>
            <description>A single dose of 5 mg of CTZ oral drops was administered orally on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cetirizine (CTZ) 10 mg</title>
            <description>A single dose of 10 mg of CTZ oral tablet was administered orally on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Individual Symptom Scores Over Period II</title>
          <description>Individual symptom scores include Runny Nose Score, Itchy Nose Score, Sniffles Score, Watery Eyes Score, Sneezes Score, Nose Blows Score.
The subjects had to evaluate the severity of the symptoms using a scale from &quot;None&quot; to &quot;Very severe&quot; (ranging from 0 to 5).
For Sneezes Score and Nose Blows Score, the subjects had to record the number of each symptom since last evaluation. This number corresponds to a score ranging from 0 to 8.
Increasing scores are associated with increasing severity. Negative values indicate improvement from Baseline.</description>
          <population>Only subjects with valid individual symptom scores in Period II were included in the analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="119"/>
                <count group_id="O5" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Runny Nose Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.62" spread="0.122"/>
                    <measurement group_id="O2" value="-0.86" spread="0.098"/>
                    <measurement group_id="O3" value="-0.94" spread="0.098"/>
                    <measurement group_id="O4" value="-0.95" spread="0.097"/>
                    <measurement group_id="O5" value="-1.10" spread="0.098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itchy Nose Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="0.120"/>
                    <measurement group_id="O2" value="-1.00" spread="0.097"/>
                    <measurement group_id="O3" value="-1.11" spread="0.097"/>
                    <measurement group_id="O4" value="-1.13" spread="0.096"/>
                    <measurement group_id="O5" value="-1.24" spread="0.096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sniffles Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="0.127"/>
                    <measurement group_id="O2" value="-0.91" spread="0.103"/>
                    <measurement group_id="O3" value="-0.96" spread="0.102"/>
                    <measurement group_id="O4" value="-0.90" spread="0.101"/>
                    <measurement group_id="O5" value="-1.21" spread="0.102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nose Blow Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" spread="0.162"/>
                    <measurement group_id="O2" value="-1.61" spread="0.131"/>
                    <measurement group_id="O3" value="-1.84" spread="0.131"/>
                    <measurement group_id="O4" value="-1.78" spread="0.130"/>
                    <measurement group_id="O5" value="-2.02" spread="0.130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sneezes Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="0.112"/>
                    <measurement group_id="O2" value="-1.18" spread="0.091"/>
                    <measurement group_id="O3" value="-1.33" spread="0.090"/>
                    <measurement group_id="O4" value="-1.19" spread="0.089"/>
                    <measurement group_id="O5" value="-1.38" spread="0.090"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Watery Eyes Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="0.119"/>
                    <measurement group_id="O2" value="-0.78" spread="0.097"/>
                    <measurement group_id="O3" value="-0.91" spread="0.096"/>
                    <measurement group_id="O4" value="-0.83" spread="0.096"/>
                    <measurement group_id="O5" value="-0.93" spread="0.096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Individual Symptom Scores Over the Total Treatment Period (Period I + Period II)</title>
        <description>Individual symptom scores include Runny Nose Score, Itchy Nose Score, Sniffles Score, Watery Eyes Score, Sneezes Score, Nose Blows Score.
The subjects had to evaluate the severity of the symptoms using a scale from &quot;None&quot; to &quot;Very severe&quot; (ranging from 0 to 5).
For Sneezes Score and Nose Blows Score, the subjects had to record the number of each symptom since last evaluation. This number corresponds to a score ranging from 0 to 8.
Increasing scores are associated with increasing severity. Negative values indicate improvement from Baseline.</description>
        <time_frame>Baseline to Day 2</time_frame>
        <population>Only subjects with valid individual symptom scores in Period I and II were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO)</title>
            <description>A single dose of placebo was administered orally on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Levocetirizine (LCTZ) 2.5 mg</title>
            <description>A single dose of 2.5 mg of LCTZ oral drops was administered orally on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Levocetirizine (LCTZ) 5 mg</title>
            <description>A single dose of 5 mg of LCTZ oral tablet was administered orally on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cetirizine (CTZ) 5 mg</title>
            <description>A single dose of 5 mg of CTZ oral drops was administered orally on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cetirizine (CTZ) 10 mg</title>
            <description>A single dose of 10 mg of CTZ oral tablet was administered orally on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Individual Symptom Scores Over the Total Treatment Period (Period I + Period II)</title>
          <description>Individual symptom scores include Runny Nose Score, Itchy Nose Score, Sniffles Score, Watery Eyes Score, Sneezes Score, Nose Blows Score.
The subjects had to evaluate the severity of the symptoms using a scale from &quot;None&quot; to &quot;Very severe&quot; (ranging from 0 to 5).
For Sneezes Score and Nose Blows Score, the subjects had to record the number of each symptom since last evaluation. This number corresponds to a score ranging from 0 to 8.
Increasing scores are associated with increasing severity. Negative values indicate improvement from Baseline.</description>
          <population>Only subjects with valid individual symptom scores in Period I and II were included in the analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="119"/>
                <count group_id="O4" value="119"/>
                <count group_id="O5" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Runny Nose Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" spread="0.093"/>
                    <measurement group_id="O2" value="-0.94" spread="0.076"/>
                    <measurement group_id="O3" value="-0.95" spread="0.075"/>
                    <measurement group_id="O4" value="-1.07" spread="0.075"/>
                    <measurement group_id="O5" value="-1.06" spread="0.075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itchy Nose Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.61" spread="0.097"/>
                    <measurement group_id="O2" value="-1.02" spread="0.080"/>
                    <measurement group_id="O3" value="-1.10" spread="0.079"/>
                    <measurement group_id="O4" value="-1.21" spread="0.079"/>
                    <measurement group_id="O5" value="-1.16" spread="0.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sniffles Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" spread="0.098"/>
                    <measurement group_id="O2" value="-1.05" spread="0.080"/>
                    <measurement group_id="O3" value="-1.02" spread="0.079"/>
                    <measurement group_id="O4" value="-1.09" spread="0.079"/>
                    <measurement group_id="O5" value="-1.15" spread="0.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nose Blow Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.98" spread="0.124"/>
                    <measurement group_id="O2" value="-1.75" spread="0.102"/>
                    <measurement group_id="O3" value="-1.83" spread="0.100"/>
                    <measurement group_id="O4" value="-1.86" spread="0.101"/>
                    <measurement group_id="O5" value="-1.99" spread="0.100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sneezes Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="0.090"/>
                    <measurement group_id="O2" value="-1.17" spread="0.074"/>
                    <measurement group_id="O3" value="-1.19" spread="0.073"/>
                    <measurement group_id="O4" value="-1.21" spread="0.073"/>
                    <measurement group_id="O5" value="-1.31" spread="0.073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Watery Eyes Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="0.089"/>
                    <measurement group_id="O2" value="-0.87" spread="0.073"/>
                    <measurement group_id="O3" value="-1.01" spread="0.072"/>
                    <measurement group_id="O4" value="-1.00" spread="0.073"/>
                    <measurement group_id="O5" value="-1.01" spread="0.072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from Day 1 until up to 9 days after the study drug intake.</time_frame>
      <desc>Adverse Events refer to the Safety Population consisting of all subjects who were dispensed medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo (PBO)</title>
          <description>A single dose of placebo was administered orally on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Levocetirizine (LCTZ) 2.5 mg</title>
          <description>A single dose of 2.5 mg of LCTZ oral drops was administered orally on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>Levocetirizine (LCTZ) 5 mg</title>
          <description>A single dose of 5 mg of LCTZ oral tablet was administered orally on Day 1.</description>
        </group>
        <group group_id="E4">
          <title>Cetirizine (CTZ) 5 mg</title>
          <description>A single dose of 5 mg of CTZ oral drops was administered orally on Day 1.</description>
        </group>
        <group group_id="E5">
          <title>Cetirizine (CTZ) 10 mg</title>
          <description>A single dose of 10 mg of CTZ oral tablet was administered orally on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Defaecation urgency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry throat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Nasal dryness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Nasal mucosal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Throat tightness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Periorbital oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>UCB</name_or_title>
      <organization>UCB S.A.</organization>
      <phone>+1844 599 ext 2273</phone>
      <email>UCBCares@ucb.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

